| 1.93 0.03 (1.58%) | 04-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.48 | 1-year : | 2.9 |
| Resists | First : | 2.13 | Second : | 2.48 |
| Pivot price | 1.91  |
|||
| Supports | First : | 1.83 | Second : | 1.64 |
| MAs | MA(5) : | 1.94 |
MA(20) : | 1.92 |
| MA(100) : | 2.62 |
MA(250) : | 5.15 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 46.5 |
D(3) : | 49.8 |
| RSI | RSI(14): 48.9 |
|||
| 52-week | High : | 16.68 | Low : | 1.64 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BJDX ] has closed below upper band by 40.7%. Bollinger Bands are 69.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 77 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2 - 2.01 | 2.01 - 2.02 |
| Low: | 1.84 - 1.86 | 1.86 - 1.87 |
| Close: | 1.88 - 1.9 | 1.9 - 1.92 |
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Mon, 20 Apr 2026
Board seeks flexible reverse split, plan increase at Bluejay Diagnostics (NASDAQ: BJDX) - Stock Titan
Mon, 20 Apr 2026
BJDX Ownership | BLUEJAY DIAGNOSTICS INC (NASDAQ:BJDX) - ChartMill
Tue, 07 Apr 2026
Bluejay nears finish line in sepsis test study with 624 patients - Stock Titan
Thu, 02 Apr 2026
Are insiders buying or selling Bluejay Diag (BJDX) Stock | Price at $1.95, Up 3.17% - Viral Momentum Stocks - Xã Vĩnh Công
Wed, 11 Mar 2026
Braeden Lichti Pushes for Changes at Bluejay Diagnostics with 3.65% Stake - TradingView
Fri, 20 Feb 2026
Bluejay Diagnostics says all prefunded warrants exercised; ~972,000 shares outstanding, 1.5M cash-exercise warrants - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 5.1 (%) |
| Held by Institutions | 4 (%) |
| Shares Short | 43 (K) |
| Shares Short P.Month | 37 (K) |
| EPS | -15.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -62.8 % |
| Return on Equity (ttm) | -117.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.13 |
| PEG Ratio | 0 |
| Price to Book value | 0.19 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|